190 related articles for article (PubMed ID: 37863651)
1. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.
Karimpour M; Totonchi M; Behmanesh M; Montazeri H
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37863651
[TBL] [Abstract][Full Text] [Related]
2. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
3.
Sun N; Petiwala S; Lu C; Hutti JE; Hu M; Hu M; Domanus MH; Mitra D; Addo SN; Miller CP; Chung N
CRISPR J; 2019 Aug; 2():230-245. PubMed ID: 31436504
[TBL] [Abstract][Full Text] [Related]
4. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
[TBL] [Abstract][Full Text] [Related]
5. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
[TBL] [Abstract][Full Text] [Related]
6. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
Ye H; Zhang X; Chen Y; Liu Q; Wei J
Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
[TBL] [Abstract][Full Text] [Related]
7. CRISPR screens identify a novel combination treatment targeting BCL-X
Jung HR; Oh Y; Na D; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Jeong EM; An JY; Sung CO; Lee WS; Lee C; Cho SY
Oncogene; 2021 May; 40(18):3287-3302. PubMed ID: 33846570
[TBL] [Abstract][Full Text] [Related]
8. Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
Valentino JD; Elliott VA; Zaytseva YY; Rychahou PG; Mustain WC; Wang C; Gao T; Evers BM
Surgery; 2012 Aug; 152(2):277-85. PubMed ID: 22828149
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
10. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
Wang X; Zhang Y; Han ZG; He KY
Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
[TBL] [Abstract][Full Text] [Related]
11. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
12. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
13. Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens.
Srivatsa S; Montazeri H; Bianco G; Coto-Llerena M; Marinucci M; Ng CKY; Piscuoglio S; Beerenwinkel N
Nat Commun; 2022 Dec; 13(1):7748. PubMed ID: 36517508
[TBL] [Abstract][Full Text] [Related]
14. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
15. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
Srihari S; Singla J; Wong L; Ragan MA
Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
[TBL] [Abstract][Full Text] [Related]
16. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.
Yang Z; Liang SQ; Zhao L; Yang H; Marti TM; Hegedüs B; Gao Y; Zheng B; Chen C; Wang W; Dorn P; Kocher GJ; Schmid RA; Peng RW
J Exp Clin Cancer Res; 2022 Jan; 41(1):25. PubMed ID: 35039048
[TBL] [Abstract][Full Text] [Related]
17. SL-scan identifies synthetic lethal interactions in cancer using metabolic networks.
Zangene E; Marashi SA; Montazeri H
Sci Rep; 2023 Sep; 13(1):15763. PubMed ID: 37737478
[TBL] [Abstract][Full Text] [Related]
18. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
20. Extensive genomic analysis in patients with
Jacobsen IC; Spanggaard I; Højgaard M; Belcaid L; Qvortrup C; Yde CW; Schmidt AY; Nielsen FC; Willemoe GL; Dam MS; Lassen U; Staal Rohrberg K
Acta Oncol; 2022 Dec; 61(12):1499-1506. PubMed ID: 36529989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
